<DOC>
	<DOCNO>NCT00077194</DOCNO>
	<brief_summary>This phase II trial study well FR901228 work treat patient relapsed refractory non-Hodgkin 's lymphoma . Drugs use chemotherapy , FR901228 , work different way stop tumor cell divide stop grow die .</brief_summary>
	<brief_title>FR901228 Treating Patients With Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate ( complete partial ) patient relapse refractory Burkitt 's , mantle cell diffuse large cell non-Hodgkin 's lymphoma treat FR901228 ( depsipeptide ) . II . Determine safety feasibility drug , term incidence maximum grade toxicity course delay dos reduce , patient . III . Determine 2-year progression-free survival overall survival patient treated drug . IV . Correlate tumor expression BCL-2 , BCL-6 , BAX , RAS response patient treated drug . OUTLINE : This multicenter study . Patients receive FR901228 ( depsipeptide ) IV 4 hour day 1 , 8 , 15 . Treatment repeat every 28 day least 6 course absence disease progression unacceptable toxicity . Patients follow every 3 month disease progression every 6 month 5 year study registration .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm aggressive Bcell nonHodgkin 's lymphoma 1 follow cellular type : Diffuse large cell Mantle cell Burkitt 's Relapsed refractory disease No 2 prior regimen patient refractory disease Any number prior therapy ( include peripheral blood stem cell bone marrow transplantation ) allow patient relapsed disease provide objective response recent therapy Measurable disease At least 1 lesion ≥ 1.5 cm diameter No transform lymphoma No CNS lymphoma Ineligible , refuse , relapsed stem cell transplantation PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Hematopoietic Absolute neutrophil count ≥ 1,000/mm^3 ( 500/mm^3 patient extensive bone marrow involvement [ &gt; 50 % ] hypersplenism palpable splenomegaly ) Platelet count ≥ 75,000/mm^3 ( 50,000/mm^3 patient extensive bone marrow involvement hypersplenism palpable splenomegaly ) Hepatic Bilirubin ≤ upper limit normal ( ULN ) Alkaline phosphatase ≤ 2 time ULN AST ≤ 2 time ULN Renal Creatinine ≤ ULN Cardiovascular QTc &lt; 500 msec ECG Cardiac function ≥ 50 % MUGA No prior serious ventricular arrhythmia No New York Heart Association class III IV congestive heart failure No significant cardiac hypertrophy ECG No significant cardiac disease Pulmonary No chronic obstructive pulmonary disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No active infection No diabetes No uncontrolled serious medical condition PRIOR CONCURRENT THERAPY : Chemotherapy Prior cumulative doxorubicin dose &lt; 450 mg/m^2 Prior cumulative mitoxantrone dose &lt; 112 mg/m^2 Prior doxorubicin equivalent dose &lt; 450 mg/m^2 ( patient previously receive doxorubicin mitoxantrone ) Other Recovered prior therapy No prior histone deacetylase inhibitor therapy No concurrent medication associate QTc prolongation , dolasetron Concurrent hydrochlorothiazide , furosemide , diuretic allow provided patient concurrent potassium chloride supplementation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2005</verification_date>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
</DOC>